Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00068042 · ClinicalTrials.gov registry record · Phase 4

A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly

A Phase 4 study of Acromegaly, sponsored by Pfizer.

Completed
Registry status
Phase 4
Development phase
100
Enrollment target
20
Study locations

NCT00068042 is a Phase 4 study of Acromegaly that has completed, run by Pfizer. The registered enrollment target is 100 participants, roughly in line with the 93-participant average among 13 other Acromegaly trials with a reported enrollment target. The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00068042, a Phase 4 study of Acromegaly, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 4
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.

Conditions Studied

Acromegaly

Interventions

  • DRUG Pegvisomant
  • DRUG Sandostatin LAR

Study Locations (20)

Illinois

  • Pfizer Investigational Site - Chicago
  • Pfizer Investigational Site - Chicago

Michigan

  • Pfizer Investigational Site - Ann Arbor
  • Pfizer Investigational Site - Ann Arbor

New South Wales

  • Pfizer Investigational Site - Darlinghurst
  • Pfizer Investigational Site - Westmead

Victoria

  • Pfizer Investigational Site - Fitzroy
  • Pfizer Investigational Site - Heidelberg

California

  • Pfizer Investigational Site - Los Angeles

Massachusetts

  • Pfizer Investigational Site - Boston

New York

  • Pfizer Investigational Site - New York

North Carolina

  • Pfizer Investigational Site - Chapel Hill

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2003-04
Est. Completion 2006-05
Phase Phase 4

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00068042

The ClinicalTrials.gov registry entry for NCT00068042 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 93-participant average among 13 other Acromegaly trials with a reported enrollment target. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acromegaly appearing as the primary indexed condition, and to 2 interventions - of which Pegvisomant is the first listed.

NCT00068042 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Illinois, Michigan, New South Wales.

Frequently Asked Questions

What is clinical trial NCT00068042 about?

NCT00068042 is a clinical study titled "A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly". The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.

What is the current status of trial NCT00068042?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2003-04. Estimated completion is 2006-05.

What conditions does trial NCT00068042 study?

This clinical trial studies the following conditions: Acromegaly.

What interventions are being tested in trial NCT00068042?

The interventions under investigation include: Pegvisomant (DRUG), Sandostatin LAR (DRUG).

Who is sponsoring clinical trial NCT00068042?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00068042 being conducted?

This trial has 20 study locations across California, Illinois, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acromegaly

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acromegaly

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.